Health Care

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Health Care - overview

Established

2008

Location

Benxi, -, China

Primary Industry

Biotechnology

About

Health Care is a technology-driven company dedicated to providing innovative solutions that enhance operational efficiency across multiple sectors, including healthcare, logistics, and retail. The firm focuses on integrating advanced technologies tailored to the unique needs of its clients. Health Care, founded in 2008 in Benxi, China, specializes in technology solutions that support various industries. The company raised RMB 49 million in Series B funding from Jolmo Capital in February 2015, marking its second deal.


CEO Francis McCaffery leads the company, which has not undergone any significant pivots or changes in business operations since its inception. Health Care offers a range of advanced technology solutions designed to streamline operations for businesses in healthcare, logistics, and retail. These solutions enhance efficiency and productivity while addressing specific industry challenges. The company's client base includes both small enterprises and large corporations, particularly in North America and Europe, where there's a demand for integrated technology solutions.


In the most recent year, 2021, Health Care reported revenue of CNY 186,323. 6 with an EBITDA of CNY -2,087,725. 9. The company generates income through a mix of direct sales and subscription services, primarily through B2B transactions where clients engage for tailored solutions and ongoing support.


Health Care plans to leverage its recent funding to develop and launch new products designed to meet the evolving needs of the market. The company aims to expand its presence in emerging markets in Asia by 2025, focusing on regions that show potential for technological advancement. The funding from its Series B round will be utilized to support these product developments and market expansions.


Current Investors

Cowin Capital, Jolmo Capital

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals

Website

www.lnzhk.com

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.